Oncaspar liquid (pegaspargase) / Servier - LARVOL DELTA

Baseline total lesion glycolysis identifies high-risk patients with immunosuppressive signatures in early-stage natural killer/T-cell lymphoma. (PubMed, Oncologist) - "Baseline TLG reflected an immunosuppressive microenvironment and was an effective radiomic marker for long-term remission in patients with early-stage NKTCL."

Journal • Epstein-Barr Virus Infections • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission. (PubMed, Br J Haematol) - "The majority (84.6%) of patients were able to receive over half of their planned pegaspargase doses. The incorporation of blinatumomab consolidation to C10403 is safe and feasible in adults with ALL."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Inflammation • Leukemia • Oncology • Pediatrics • Psychiatry • Transplantation

A Study Comparing the Combination of Dasatinib or Imatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov) - P3 | N=222 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | N=680 ➔ 222

Enrollment change • Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • CD19 • CSF1R • KIT • PDGFRA • PDGFRB

Chemoinduction therapy and its response in Jehovah's Witnesses with acute lymphoblastic leukemia: A systematic review. (ASCO 2025) - "B12, filgrastim, and romiplostim were administered in an attempt to maintain hematological parameters, in response to chemotherapy-induced myelosuppression...For chemotherapeutic induction, the majority of the studies utilized vincristine-based combinations with drugs including cyclophosphamide, doxorubicin, methotrexate, prednisolone, rituximab, pegaspargase also being used... Our systematic review shows that it is possible to achieve complete remission in a majority of Jehovah's Witnesses with ALL using chemotherapeutic induction. The myelosuppressive effects of chemo-induction, in the absence of blood and blood-product transfusions, present a substantial clinical challenge, supportive agents allow us to counteract this to a considerable degree. Careful supportive management enables remission, though long-term survival remains uncertain."

Review • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma (clinicaltrials.gov) - P2 | N=57 | Recruiting | Sponsor: Peking University Cancer Hospital & Institute

New P2 trial • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Dec 2024 ➔ Dec 2027

Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pediatrics • ABL1 • BCR

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax (clinicaltrials.gov) - P1/2 | N=35 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial completion date: Mar 2025 ➔ Feb 2027

Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

A Novel Liquid Chromatography-Tandem Mass Spectrometry Method for Monitoring Plasma l-Asparaginase Activity in Pediatric Patients With Acute Lymphoblastic Leukemia Receiving Pegaspargase Treatment. (PubMed, Ther Drug Monit) - "This method was fully validated and successfully applied to quantify l-asparaginase activity in plasma samples of 15 children with ALL, enabling the monitoring of l-asparaginase activity with mass spectrometry."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

VENETOCLAX, TUCIDINOSTAT, PEGASPARGASE, AND DEXAMETHASONE INDUCTION REGIMEN FOR NEWLY DIAGNOSED ADULT ETP-ALL: A CHEMOTHERAPY-FREE, LOW-TOXICITY, EFFECTIVE REGIMEN (EHA 2025) - "BEAT chemofree induction regimen is a promising regimen in newly diagnosed adult ETP-ALL, with high CR/CRi and well-tolerated."

Clinical • Anemia • Bone Marrow Transplantation • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Oncology • Pediatrics • Respiratory Diseases • T Acute Lymphoblastic Leukemia • Thrombocytopenia • KMT2A

A NOVEL TREATMENT REGIMEN FOR NEWLY DIAGNOSED CAEBV INDUCING A HIGH RESPONSE RATE: PD-1 INHIBITOR, L-ASPARGASE AND CHIDAMIDE (EHA 2025) - "The P-P-Chi regimen (Sintilimab + Pegaspargase + Chidamide) demonstrated significant efficacy and favorable safety in CAEBV as a first-line therapy, warranting further clinical trials and broader application."

Anemia • Anorexia • Bone Marrow Transplantation • CNS Disorders • Epstein-Barr Virus Infections • Fatigue • Fibrosis • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Leukopenia • Liver Failure • Neutropenia • Novel Coronavirus Disease • Rare Diseases • Respiratory Diseases • Thrombocytopenia

IMPACT OF RELATIVE DOSE INTENSITY OF CHEMOTHERAPY IN ELDERLY PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA (EHA 2025) - "RDI was calculated for first-line regimens incorporating pegaspargase (PEG-Asp), platinum antineoplastic agents (included cisplatin or oxaliplatin), and gemcitabine (GEM) using a standardized approach: (1) Standard dose intensity (SDI): SDI = planned dose per cycle (mg/m²) / planned cycle duration (weeks). Optimal RDI thresholds in elderly NKTCL pts require multicenter validation. Higher dose intensity correlates with improved survival, but toxicity management is crucial to reduce treatment delays."

Clinical • Anemia • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma

A CAMPUS ALL RETROSPECTIVE MULTICENTER STUDY ON THE OUTCOME OF ADULT LYMPHOBLASTIC LYMPHOMA PATIENTS TREATED IN THE REAL-LIFE ACCORDING TO THE GIMEMA LAL1913 PROTOCOL (EHA 2025) - "Briefly, pegaspargase was added at cycles 1 (in addition to idarubicine, vincristine, HCD-dexamethasone); 2, 4, 6 (in addition to idarubicine, vincristine, HCD dexamethasone and cyclophosphamide) and 5 (in addition to only higher doses (HD) methotrexate). Cycles 3 and 7 were pegaspargase-free being combined with methotrexate HD and cytarabine HD... Our study shows very promising results in terms of OS, DFS and EFS (Figure 1a), especially if we take into account that it is based on a drug combination never tested before in a real-life setting. Bearing in mind the successful use of pegaspargase even in the presence of a dose-reduction, the results observed with the LAL1913-based protocol in the real-life suggest that it may be considered as a reference for the frontline treatment of adult LL-patients."

Retrospective data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Genetic Disorders • Hematological Malignancies • Leukemia • Lymphoma • Obesity • Oncology • Pediatrics • CD1a

LATEST UPDATE RESULTS OF P-GEMD REGIMEN IN NEWLY DIAGNOSED EARLY NON-UPPER AERO-DIGESTIVE TRACT OR ADVANCED STAGE EXTRANODAL NK/T CELL LYMPHOMA (EHA 2025) - P2 | "At the 2024 ASH annual meeting (Abstract 6396), preliminary efficacy and manageable safety of pegaspargase combined with gemcitabine, etoposide, mitoxantrone hydrochloride liposome, and dexamethasone (P-GEMD) regimen in newly diagnosed early NUAT or advanced-stage ENKTL were reported, showing an objective response rate (ORR) of 87.5% and a complete response (CR) rate of 81.3%. P-GEMD regimen has shown encouraging preliminary anti-tumor activity with manageable toxicities as a front-line treatment for early NUAT or advanced stage ENKTL. These results support further randomized controlled trial (RCT) to confirm activity and assess efficacy in this population."

Metastases • Anemia • Cardiovascular • Endocrine Disorders • Epstein-Barr Virus Infections • Heart Failure • Hematological Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Leukopenia • Lymphoma • Natural Killer/T-cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Rare Diseases • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia

PEGASPARGASE ADMINISTRATION IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS AGED 55 YEARS OR OLDER TREATED WITH THE PEDIATRIC-INSPIRED PROGRAM LAL1913. A SUBANALYSIS OF THE CAMPUS ALL STUDY (EHA 2025) - "In this real-world setting, including 90 ALL pts aged over 55 years, fit for intensive chemotherapy and treated homogeneously with a pediatric-inspired protocol, 96% of cases received PEG-ASP in at least one of the first two chemotherapy courses. Our analysis confirms the feasibility of PEG-ASP administration in fit older ALL pts. Clinicians' expertise in dose adjustment according to pts age and comorbidities is very important to balance efficacy and toxicity."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Leukemia • Obesity • Oncology • Pediatrics

REAL WORLD ANALYSIS OF OUTCOMES USING A MODIFIED DFCI PROTOCOL FOR ADULTS WITH BCR-ABL NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA - IMPACT OF MRD (EHA 2025) - "From 2020-24 pegaspargase was substituted for native E. coli asparaginase...Blinatumomab was not used for MRD negative patients, but was used for MRD+ B-ALL patients after 2019... For patients receiving a modified DFCI protocol, MRD positivity >0.1% post-induction predicts for inferior DFS and OS in patients age >35. There was no evidence of improved outcomes with SCT in MRD+ patients. MRD negativity predicts for a favorable outcome with approx."

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Septic Shock • T Acute Lymphoblastic Leukemia • ABL1 • BCR

Economic Burden of Switching From Frontline to Second-Line Asparaginase in Pediatrics With ALL (ASPHO 2025) - "Background: Long-acting E.coli asparaginases (pegaspargase [PEG] and calaspargase pegol [CAL-PEG]) are critical components of frontline (1L) chemotherapy regimens in childhood acute lymphoblastic leukemia (ALL). Switching from 1L to 2L asparaginase is relatively common in pediatric ALL patients, which significantly increases treatment costs, mainly driven by higher outpatient medical costs of recombinant Erwinia. Consideration should be given to performing TDM, which may have important implications for mitigating unnecessary switches, as well as achieving substantial cost savings for payers."

Clinical • HEOR • Acute Lymphocytic Leukemia • Hematological Malignancies • Immunology • Leukemia • Oncology • Pediatrics

Managing Hypersensitivity Reactions After Asparaginase Treatment: A Systematic Literature Review (ASPHO 2025) - "As pediatric patients transitioned from pegaspargase (PEG) to calaspargase pegol (CAL-PEG) beginning December 2022, recent congress abstracts were searched post-SLR completion to capture data on CAL-PEG. HSRs are common with ASP, with varying prevalence across ASP formulations and protocols. This SLR demonstrated increasing use of premedication, despite insufficient evidence on its effectiveness. Large studies on desensitization are lacking, with small studies showing variable rates of success."

Review • Acute Lymphocytic Leukemia • Hematological Malignancies • Immunology • Leukemia • Oncology • Pediatrics

CHARACTERIZING CHEMOTHERAPY-ASSOCIATED DRUG-INDUCED LIVER INJURY (DDW 2025) - "Interestingly, in these patients, the drugs associated with highest frequency of abnormal LFTs were pegaspargase, vincristine, tretinoin, and cytarabine ( Table 2 ). These data suggest that the development of abnormal LFTs after treatment with chemotherapeutic agents is common, and given the design of this study, that such abnormalities are due to DILI. The findings also raise the possibility that there is substantial underreporting of DILI in typical clinical settings."

Biliary Cancer • Hepatology • Infectious Disease • Liver Failure • Metabolic Dysfunction-Associated Steatohepatitis • Oncology

Pegaspargase induced multiple organ failure with acute lymphoblastic leukemia: A case report. (PubMed, World J Clin Cases) - "This is the first case report of successful treatment of pegaspargase-induced multiple organ failure. The findings emphasize the importance of a multidisciplinary team approach in treating pegaspargase-induced multiple organ failure."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Hepatology • Leukemia • Liver Failure • Oncology • AFP

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (clinicaltrials.gov) - P2/3 | N=790 | Active, not recruiting | Sponsor: St. Jude Children's Research Hospital | Trial completion date: Mar 2028 ➔ Sep 2028

Trial completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • BCL2

Clinical Analysis of Extranodal NK/T-Cell Lymphoma, Nasal Type with Skin Lesions as Initial Symptom (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi) - "Early clinical symptoms of ENKTL patients with skin lesions as initial symptom are more atypical, and early diagnosis is particularly difficult. The disease progresses rapidly and the prognosis is poor. There is still no uniform standard for the best treatment strategy. The survival of patients can be significantly prolonged by applying ASCT as soon as possible after complete remission obtained by high-dose induction chemotherapy."

Journal • Retrospective data • Bone Marrow Transplantation • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • Pain • Rare Diseases • T Cell Non-Hodgkin Lymphoma • Transplantation • NCAM1

Camrelizumab plus low–dose apatinib and pegaspargase followed by radiotherapy for newly diagnosed stage I/II natural killer/T–cell lymphoma: a multicenter phase II study (ICML 2025) - No abstract available

Clinical • P2 data • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma: Analysis of the Phase Ib Part (ICML 2025) - No abstract available

Metastases • P1 data • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Magnetic Resonance Screening for Cerebral Venous Sinus Thrombosis during Treatment with Pegaspargase. (PubMed, Semin Thromb Hemost) - "This study highlights a significant incidence of PEG-ASP-related CVST in children, with MRV screening revealing a notably higher detection rate than previously reported. Most cases were asymptomatic, which demonstrated better prognoses, emphasizing the importance of MRV for early CVST diagnosis after induction remission in ALL/LBL."

Journal • Acute Lymphocytic Leukemia • Cardiovascular • CNS Disorders • Epilepsy • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pain • Pediatrics • Psychiatry • Schizophrenia • Thrombosis

A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. (clinicaltrials.gov) - P3 | N=60 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P3 trial • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma